EXPERIMENTAL EVALUATION OF TIGECYCLINE AND TEIKOPLANIN IN THE TREATMENT OF IMPLANT RELATED METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) OSTEOMYELITIS

Basit Öğe Kaydı
dc.authoridKaraduman, Zekeriya Okan/0000-0002-6719-3666
dc.contributor.authorOrhan, Zafer
dc.contributor.authorDegirmenci, Erdem
dc.contributor.authorOktas, Birhan
dc.contributor.authorKaraduman, Okan
dc.contributor.authorKir, Gozde
dc.contributor.authorMulazimoglu, Lutfiye
dc.date.accessioned2025-01-21T16:40:54Z
dc.date.available2025-01-21T16:40:54Z
dc.date.issued2014
dc.departmentKırıkkale Üniversitesi
dc.description.abstractTreatment of implant related MRSA osteomyelitis is a real challenge both for the physician and the patient. We evaluated the comparative efficacy of tigecycline, a novel broad-spectrum glycycline antibiotic and the glycopeptide antibiotic teicoplanin in the treatment of implant related MRSA osteomyelitis in an experimental rat model. Implant related MRSA osteomyelitis was studied in tibial metaphysis of 60 rats. When compared to the control groups, the number of microorganisms was found to be significantly lower in the study groups, but there was no statistically significant difference between tigecycline and teicoplanin respectively. Tigecycline with its good tissue penetration and lower side effects was found to be as effective as teicoplanin in implant related MRSA osteomyelitis, even if the implant is retained. It could be considered as an alternative to glycopeptides because of the efficacy and because of the lower adverse effects in long term usage. Further studies are warranted to suggest a standard medical treatment for implant-related osteomyelitis.
dc.description.sponsorshipDuzce University
dc.description.sponsorshipWe thank Duzce University for the support of this work.
dc.identifier.doi10.13040/IJPSR.0975-8232.5(10).4566-73
dc.identifier.endpage4573
dc.identifier.issn0975-8232
dc.identifier.issue10
dc.identifier.startpage4566
dc.identifier.urihttps://doi.org/10.13040/IJPSR.0975-8232.5(10).4566-73
dc.identifier.urihttps://hdl.handle.net/20.500.12587/24790
dc.identifier.volume5
dc.identifier.wosWOS:000215491000061
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherInt Journal Pharmaceutical Sciences & Research
dc.relation.ispartofInternational Journal of Pharmaceutical Sciences and Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectMRSA; Experimental implant-related osteomyelitis; Tigecycline; Teicoplanin
dc.titleEXPERIMENTAL EVALUATION OF TIGECYCLINE AND TEIKOPLANIN IN THE TREATMENT OF IMPLANT RELATED METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) OSTEOMYELITIS
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu